New blood-thinning drug safer than rat poisonSeptember 30, 2009In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects. The original paper, Dabigatran versus warfarin in patients with atrial fibrillation, by Neal Devaraj and Stuart Connolly et al. in the New England Journal of Medicine, says warfarin (also commonly used in rat poison) has several drawbacks. Finding the correct dosage requires careful and laborious monitoring, and the risk of major bleeding has led to it being under-used. With fewer side-effects and complications than warfarin, the reviewers see many potential benefits from dabigatran. According to Olshansky, it is "perhaps one of the important drug discoveries in the past decade." Ruilope says that according to the investigators, "This oral anticoagulant prevents strokes and peripheral embolic events in patients with atrial fibrillation significantly better than that much older drug (warfarin) at different doses. It is also safer than warfarin with respect to major bleeding events." "An immediate change of practice is not warranted but a change in standard anticoagulant therapy may be needed," Ruilope says. Faculty of 1000: Biology and Medicine |
|||||||||||||||||||||
| Related Warfarin Current Events and Warfarin News Articles Dabigatran vs. warfarin as long-term anticoagulant therapy in atrial fibrillation The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study (Randomized Evaluation of Long-term anticoagulant therapY). Monash researchers lead the way in blood clotting discovery A Monash-led research team has discovered an entirely new mechanism that promotes blood clot formation - a major breakthrough that will impact on treatment and prevention of heart disease and stroke. More patients needed in clinical trials to find treatment for heart condition linked to certain strokes The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth. Is it reasonable to perform polypectomy without interruption of anticoagulation? Currently, patients taking anticoagulants to prevent stroke and blood clots are often recommended to stop these medications in order to perform colonoscopy with removal of polyps. Right warfarin dose determined by 3 genes Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics. Genetic information personalizes warfarin prescribing Warfarin, one of the world's most widely used drugs, is also one of the trickiest to prescribe. Half of those who take it are at risk of serious problems when given the standard starting dose. Mutant rats offer clues to medical mystery A research project at Rice University has brought scientists to the brink of comprehending a long-standing medical mystery that may link cardiovascular disease, osteoporosis and perhaps even Alzheimer's disease. Mutant rats resist warfarin A new series of mutations have been discovered that allow rats to resist the effects of the popular poison warfarin. Research published in the open access journal BMC Genetics describes eighteen new genetic changes found in rats from four continents. Genetic testing not cost-effective in guiding initial dosing of common blood thinner New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding. Study shows optimal dose management of warfarin improves anticoagulation control Researchers from Boston University School of Medicine (BUSM) have determined the optimal dose-management strategy to derive maximal benefit from warfarin therapy and improve patient outcomes. Results of the study appear online in the December 2008 issue of the Journal of Thrombosis and Haemostasis. More Warfarin Current Events and Warfarin News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||